SNN - Smith & Nephew plc

NYSE - NYSE Delayed Price. Currency in USD
38.39
-0.55 (-1.41%)
At close: 4:02PM EDT

38.28 -0.11 (-0.29%)
Pre-Market: 7:08AM EDT

Stock chart is not supported by your current browser
Previous Close38.94
Open38.86
Bid38.24 x 800
Ask38.30 x 1000
Day's Range38.35 - 38.94
52 Week Range32.22 - 40.78
Volume703,142
Avg. Volume566,759
Market Cap16.722B
Beta (3Y Monthly)0.31
PE Ratio (TTM)25.36
EPS (TTM)1.51
Earnings DateN/A
Forward Dividend & Yield0.72 (1.80%)
Ex-Dividend Date2019-04-04
1y Target Est42.00
Trade prices are not sourced from all markets
  • Quarterly office reports noted 'unprecedented interest' to be in Pittsburgh's fringe neighborhoods
    American City Business Journals2 days ago

    Quarterly office reports noted 'unprecedented interest' to be in Pittsburgh's fringe neighborhoods

    New offices for Wabtec, Smith & Nephew and SAP helped stoke new office develop in the city's urban fringe

  • How Good Is Smith & Nephew plc (LON:SN.) At Creating Shareholder Value?
    Simply Wall St.4 days ago

    How Good Is Smith & Nephew plc (LON:SN.) At Creating Shareholder Value?

    Today we'll look at Smith & Nephew plc (LON:SN.) and reflect on its potential as an investment. Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. F...

  • London tech firm to open robotics R&D center at Stacks at 3 Crossings
    American City Business Journals8 days ago

    London tech firm to open robotics R&D center at Stacks at 3 Crossings

    London firm to take new space as first tenant at Stacks at 3 Crossings for the one-time Carnegie Mellon University robotic surgery spin off it bought for $275 million.

  • Here's Why You Should Invest in Smith & Nephew (SNN) Now
    Zacks17 days ago

    Here's Why You Should Invest in Smith & Nephew (SNN) Now

    Smith & Nephew (SNN) has been gaining investor confidence on consistently positive results.

  • Do Hedge Funds Love Smith & Nephew plc  (SNN)?
    Insider Monkey18 days ago

    Do Hedge Funds Love Smith & Nephew plc (SNN)?

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The fourth quarter of 2018 is one of those periods, as the Russell […]

  • How Much Money Does Smith & Nephew plc (LON:SN.) Make?
    Simply Wall St.21 days ago

    How Much Money Does Smith & Nephew plc (LON:SN.) Make?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you are currently a shareholder in Smith & Nephew plc (LON:SN.), or considering investing in the stock, you need to examin...

  • The Zacks Analyst Blog Highlights: Rio Tinto, Smith & Nephew, Endava, AstraZeneca and British American Tobacco
    Zackslast month

    The Zacks Analyst Blog Highlights: Rio Tinto, Smith & Nephew, Endava, AstraZeneca and British American Tobacco

    The Zacks Analyst Blog Highlights: Rio Tinto, Smith & Nephew, Endava, AstraZeneca and British American Tobacco

  • GlobeNewswirelast month

    OSIRIS THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

    WILMINGTON, Del., March 14, 2019 -- Rigrodsky & Long, P.A.: Do you own shares of Osiris Therapeutics, Inc. (NASDAQ GM: OSIR)? Did you purchase any of your shares prior to.

  • Is Britain Headed for a Soft Brexit? 5 Picks
    Zackslast month

    Is Britain Headed for a Soft Brexit? 5 Picks

    Following May's fresh legislative defeat, Britain could exit the EU while retaining access to its common market.

  • PR Newswirelast month

    Smith & Nephew POLAR3™ Total Hip Solution demonstrates best-in-class results from world's largest registry

    LONDON , March 13, 2019 /PRNewswire/ -- Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today at the American Academy of Orthopaedic Surgeons annual meeting in Las Vegas presented ...

  • Investors Who Bought Smith & Nephew (LON:SN.) Shares Five Years Ago Are Now Up 57%
    Simply Wall St.last month

    Investors Who Bought Smith & Nephew (LON:SN.) Shares Five Years Ago Are Now Up 57%

    When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking involves risks (and requires diversification) it can also provide excess returns. ForRead More...

  • PR Newswirelast month

    Smith & Nephew Acquires Brainlab Orthopaedic Joint Reconstruction Business

    The two companies enter into a strategic collaboration for future development of technology for digital surgery across a broad range of clinical areas LONDON , March 12, 2019 /PRNewswire/ --   Brainlab, ...

  • PR Newswirelast month

    Smith & Nephew establishes multi-asset digital surgery and robotic ecosystem

    LONDON, March 12, 2019 /PRNewswire/ -- Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces product launches and investments that establish its multi-asset digital surgery and robotic ecosystem. "Smith & Nephew is making a long-term commitment to bring together advanced technologies in robotics, digital surgery, and machine learning as well as augmented reality to empower surgeons and improve clinical outcomes. Currently in development, NAVIO 7.0 is the next version of Smith & Nephew's handheld robotic surgical system.

  • Reuterslast month

    Smith & Nephew to buy Osiris in regenerative products push

    The deal will help Smith & Nephew better compete with bigger rivals such as U.S.-based Johnson & Johnson as Osiris's products, including skin and bone grafts, complements its portfolio of wound care products. "Greater presence in the fast growing regenerative medicine market enhances our portfolio and will help immediately accelerate our wound management business," Smith & Nephew Chief Executive Officer Namal Nawana said.

  • Reuterslast month

    Britain's Smith & Nephew to buy Osiris in regenerative products push

    Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as the British medical products maker looks to bulk up in an area that is quickly growing. The deal will help Smith & Nephew better compete with bigger rivals such as U.S.-based Johnson & Johnson as Osiris's products, including skin and bone grafts, complements its portfolio of wound care products. "Greater presence in the fast growing regenerative medicine market enhances our portfolio and will help immediately accelerate our wound management business," Smith & Nephew Chief Executive Officer Namal Nawana said.

  • Reuterslast month

    Smith & Nephew to buy Osiris Therapeutics for $660 mln

    British medical products maker Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as it looks to boost profit margins and find ...

  • GlobeNewswirelast month

    Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc

    Osiris Therapeutics, Inc. (OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today announced that it has entered into an agreement and plan of merger with Smith & Nephew plc pursuant to which Smith & Nephew will acquire Osiris for $19.00 per share in cash, a total of approximately $660.5 million in cash. Peter Friedli, Chairman of the Board and co-founder of Osiris, said, “This is a very good outcome for Osiris’ shareholders.

  • ACCESSWIRElast month

    Sunniva Announces Closing of Second Tranche of Convertible Debt Financing for Gross Proceeds of $3.3 Million

    VANCOUVER, BC / ACCESSWIRE / March 4, 2019 / Sunniva Inc. ("Sunniva", the "Company", "we", "our" or "us") (SNN) (SNNVF), a North American provider of cannabis products and services, is pleased to announce that it has closed the second tranche of the Company's non-brokered offering (the "Financing") of convertible debentures ("Convertible Debentures") for an additional CAD $3,288,125 million, bringing total gross proceeds raised by the Financing to CAD $18,330,180 million. As previously disclosed, this Financing provides additional working capital for Sunniva to meet higher than anticipated near term sales demand for its branded cannabis products in California and for general corporate purposes.

  • TheStreet.com2 months ago

    NuVasive Stock Surges on Report of Smith & Nephew Interest

    First reported by the Financial Times late Friday, NuVasive shares jumped as much as 18% on the Nasdaq Stock Exchange in after-hours trading. Citing "people with direct knowledge of the talks," the Financial Times noted that discussions between the companies were ongoing and that no definitive deal had been reached. London-based Smith & Nephew produces a wide range of medical equipment and products, including "advanced wound management products" and orthopedic reconstruction devices.

  • Medical Stock Pops On Potential $3 Billion Smith & Nephew Takeover
    Investor's Business Daily2 months ago

    Medical Stock Pops On Potential $3 Billion Smith & Nephew Takeover

    NuVasive stock popped Monday on a report Smith & Nephew could be considering buying it for about $3 billion. NuVasive stock made double-digit percentage gains in high volume on the news.

  • NuVasive Stock Shoots Higher on Takeover Talk
    InvestorPlace2 months ago

    NuVasive Stock Shoots Higher on Takeover Talk

    NuVasive stock was on the rise Monday following news of a potential takeover from Smith & Nephew (NYSE:SNN).Source: Shutterstock The recent NuVasive (NASDAQ:NUVA) news claims that Smith & Nephew is looking to pick the company up for a price of $3 billion. This information comes from unnamed sources that are reportedly close to the takeover talks.According to these anonymous sources, the talks between NuVasive and Smith & Nephew are still ongoing and there still isn't a final agreement for the companies. As such, it is possible that the deal may not go on to reach completion, reports TheStreet.com.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNuVasive is the developer of treatments for chronic back pain and other issues with the spine. It fixes these problems with a type of minimally invasive surgery called Maximum Access Surgery. This only requires a small incision, about one inch to two inches, on the back.Smith & Nephew is a multinational l medical equipment manufacturing company. It headquarters is based out of London. The company has been around since 1856 and trades on the New York Stock Exchange, as well as the London Stock Exchange. * 10 Best Dividend Stocks to Buy for the Next 10 Months News about a possible takeover of NUVA really sent NuVasive stock soaring on Monday. The stock was up 15% as of Monday morning. However, this same news saw SNN stock dropping today. Smith & Nephew stock was down 4% as of noon Monday, but it is still up 10% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Fundamentally Sound Dividend Stocks to Buy * 5 Reasons Reeling FAANG Stocks Won't Deliver Big Returns * 3 Reasons Canopy Growth Could Burn You As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post NuVasive Stock Shoots Higher on Takeover Talk appeared first on InvestorPlace.

  • Here's Why NuVasive Stock Is Soaring Today
    Motley Fool2 months ago

    Here's Why NuVasive Stock Is Soaring Today

    The rumor mill is buzzing about a potential takeover offer. Here's what investors need to know.